B-cell malignancies and COVID-19: a narrative review

[1]  H. van Bakel,et al.  Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants , 2022, The New England journal of medicine.

[2]  Christina C. Chang,et al.  Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial , 2022, The Lancet Respiratory Medicine.

[3]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[4]  N. Gronich,et al.  Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  H. Jessen,et al.  Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial , 2022, The Lancet Respiratory Medicine.

[6]  Diane J Post,et al.  Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant , 2022, Cell Reports Medicine.

[7]  Inge Christoffer Olsen,et al.  Immunocompromised patients have been neglected in COVID-19 trials: a call for action , 2022, Clinical Microbiology and Infection.

[8]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2022, BMJ.

[9]  A. Extance.  Covid-19: What is the evidence for the antiviral molnupiravir? , 2022, BMJ.

[10]  R. Dwek,et al.  COVID-19 therapeutics: Challenges and directions for the future , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Maes,et al.  Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies , 2022, Nature Medicine.

[12]  C. Hofmeister,et al.  Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Lund-Johansen,et al.  Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination , 2022, British journal of haematology.

[14]  N. Daneman,et al.  Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. , 2022, JAMA.

[15]  B. Bailly‐Maitre,et al.  Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies , 2022, Nature Communications.

[16]  Liyuan Liu,et al.  Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.

[17]  R. Hájek,et al.  Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience , 2022, Hematological oncology.

[18]  M. Heemskerk,et al.  Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients , 2022, Blood Advances.

[19]  J. Dye,et al.  The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans , 2022, Science Translational Medicine.

[20]  I. Avivi,et al.  BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses , 2022, British journal of haematology.

[21]  Anonymous.  Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19. , 2022, JAMA.

[22]  E. Ferrant,et al.  Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients , 2022, Cancer Cell.

[23]  E. Lanoy,et al.  Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis , 2022, Leukemia.

[24]  M. Landray,et al.  Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[25]  T. Luetkens,et al.  Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy , 2021, Blood Advances.

[26]  J. Skarbinski,et al.  Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.

[27]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[28]  E. Montserrat,et al.  mRNA COVID‐19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta‐analysis , 2021, European journal of haematology.

[29]  S. Desale,et al.  Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19 , 2021, Clinical Lymphoma Myeloma and Leukemia.

[30]  C. Várnai,et al.  Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy , 2021, British journal of haematology.

[31]  L. Pagano,et al.  COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP , 2021, Blood Advances.

[32]  W. Messer,et al.  Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia , 2021, Blood Advances.

[33]  P. Pang,et al.  Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.

[34]  N. Gray,et al.  Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response , 2021, medRxiv.

[35]  L. Argaud,et al.  Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study , 2021, Journal of Intensive Care.

[36]  F. Gherlinzoni,et al.  A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study , 2021, Blood Advances.

[37]  Peter J. Richardson,et al.  Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[38]  John D. Davis,et al.  REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 , 2021, The New England journal of medicine.

[39]  S. Hober,et al.  Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients , 2021, Leukemia.

[40]  P. Chevallier,et al.  Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy , 2021, British journal of haematology.

[41]  R. Greil,et al.  Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial , 2021, The Lancet Infectious Diseases.

[42]  G. Shefer,et al.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma , 2021, Blood Advances.

[43]  M. Davids,et al.  COVID-19 in patients with CLL: improved survival outcomes and update on management strategies , 2021, Blood.

[44]  D. Skovronsky,et al.  Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 , 2021, The New England journal of medicine.

[45]  A. Davies,et al.  Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma , 2021, The Lancet Haematology.

[46]  S. Trestman,et al.  Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma , 2021, British journal of haematology.

[47]  E. Robilotti,et al.  Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 , 2021, JAMA oncology.

[48]  E. Wherry,et al.  CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer , 2021, Nature Medicine.

[49]  M. C. Muenker,et al.  Delayed production of neutralizing antibodies correlates with fatal COVID-19 , 2021, Nature Medicine.

[50]  P. Feugier,et al.  Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy , 2021, American journal of hematology/oncology.

[51]  M. Landray,et al.  Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[52]  P. Langerbeins,et al.  Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic , 2021, Acta Haematologica.

[53]  D. Ricke.  Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies , 2021, Frontiers in Immunology.

[54]  J. Díez-Martín,et al.  Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study , 2021, HemaSphere.

[55]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[56]  N. Berger,et al.  When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities , 2020, Blood Reviews.

[57]  H. Einsele,et al.  Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set , 2020, Blood.

[58]  P. Gallian,et al.  Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 , 2020, Blood.

[59]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2020, BMJ.

[60]  D. Kerr,et al.  COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.

[61]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[62]  A. Zelenetz,et al.  Outcomes of COVID-19 in patients with CLL: a multicenter international experience , 2020, Blood.

[63]  E. Montserrat,et al.  COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus , 2020, Leukemia.

[64]  J. San-Miguel,et al.  Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality , 2020, Blood Cancer Journal.

[65]  Fayzan F. Chaudhry,et al.  SARS-CoV-2 viral load predicts COVID-19 mortality , 2020, The Lancet Respiratory Medicine.

[66]  T. Liang,et al.  Decreased B Cells on Admission Associated With Prolonged Viral RNA Shedding From the Respiratory Tract in Coronavirus Disease 2019: A Case-Control Study , 2020, The Journal of infectious diseases.

[67]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[68]  J. Schachter,et al.  Early and late hematologic toxicity following CD19 CAR-T cells , 2019, Bone Marrow Transplantation.

[69]  A. Mouland,et al.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders , 2018, International Review of Cell and Molecular Biology.